Behestan Pakhsh

Brand name: Dalacin

Active ingredient (generic name): Clindamycin

Manufacturer: Pfizer

Importer: Behestan Darou

Pharmacotherapeutic group: Antibiotic

Pharmaceutical form: 150mg Capsules

Pharmacodynamic:

Clindamycin is a lincosamide antibiotic with a primarily bacteriostatic action against Gram-positive aerobes and a wide range of anaerobic bacteria. Lincosamides such as clindamycin bind to the 50S subunit of the bacterial ribosome similarly to macrolides such as erythromycin and inhibit the early stages of protein synthesis. The action of clindamycin is predominantly bacteriostatic although high concentrations may be slowly bactericidal against sensitive strains.

Pharmacokinetic:

Dalacin is absorbed completely and food has no effect on its absorption. Over 90% of clindamycin in the circulation is bound to plasma proteins. The half-life is 1.5 to 3.5 hours

Clindamycin undergoes metabolism, to the active N-demethyl and sulphoxide metabolites and also some inactive metabolites. About 10% of the drug is excreted in the urine as active drug or metabolites and about 4% in the faeces; the remainder is excreted as inactive metabolites.

Therapeutic indication:

Serious infections caused by susceptible Grampositive organisms, staphylococci (both penicillinase- and nonpenicillinase-producing), streptococci (except Streptococcus faecalis) and pneumococci. It is also indicated in serious infections caused by susceptible anaerobic pathogens such as Bacteroides spp, Fusobacterium spp, Propionibacterium spp, Peptostreptococcus spp. and microaerophilic streptococci.